Health and Healthcare

Why This Gilead Deal Is Huge For Jounce Therapeutics

Pattanaphong Khuankaew / Getty Images

Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc. (NASDAQ: GILD). This deal is for the discovery and development of novel cancer immunotherapies and predictive biomarkers.

In terms of the specifics, Gilead is exclusively licensing Jounce’s JTX-1911 program. For some quick background, JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells.

Under the terms of the agreement, Gilead will make an upfront payment of $85 million and a $35 million equity investment at a premium. Additionally, Jounce may receive up to an additional $685 million in future clinical, regulatory and commercial milestone payments. Jounce will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales.

Accordingly, Jounce will lead development of JTX-1811 through Investigational New Drug (IND) clearance. Afterwards, Gilead will have the sole right to develop JTX-1811. Currently, JTX-1811 is not approved anywhere globally and its efficacy and safety have yet to be established.

Looking forward, this antibody remains on track for filing an IND application in the first half of 2021.

Excluding Tuesday’s move, Jounce stock has underperformed the broad markets with its stock down about 45% year to date. In the past 52 weeks, the stock is up closer to 28%.

Jounce Therapeutics’ stock was last seen up about 53% at $7.40, with a 52-week range of $2.79 to $10.00. The consensus analyst price target is $10.63.

Gilead stock was last seen down about 1% at $65.85, with a 52-week range of $60.89 to $85.97. The consensus analyst price target is $77.75.

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.